Study author Erin McClure, MD, discusses how IGSRT offers consistent NMSC recurrence rates across socioeconomic and comorbidity factors, reinforcing its role as a first-line treatment.
Health Professionals
Scientists discover new weapon to fight treatment-resistant melanoma
The lab of The Wistar Institute’s Jessie Villanueva, Ph.D., has identified a new strategy for attacking treatment-resistant melanoma: inhibiting the gene S6K2. The team published their findings in the paper, “Selective abrogation of S6K2 identifies lipid homeostasis as a survival vulnerability in MAPKi-resistant NRASMUT melanoma," from the journal Science Translational Medicine.
Nivolumab Plus Relatlimab Shows Sustained PFS Benefit in Advanced Melanoma
Nivolumab (Opdivo) plus relatlimab (Opdualag) significantly improves progression-free survival (PFS) in advanced melanoma compared with anti–PD-1 monotherapy alone, according to three-year descriptive results of the RELATIVITY-047 trial that confirm the combination’s sustained benefit.
New Study Identifies Potential Genes Implicated in Treatment-Resistant Melanoma
Researchers have found that inhibiting the S6K2 gene could be an effective strategy for managing treatment-resistant melanoma, according to a recent study published by Lipchick et al in Science Translational Medicine.